Tag: senility

Grab the Popcorn: Trump Executive Privilege Decision Means All That Info on Biden Is Coming Out

President Donald Trump just made a big decision that will likely expose a lot of information that was not released about Joe Biden during his occupation of the Oval Office. 

Trump has rejected Biden’s claim of executive privilege to not turn over documents requested in various Senate probes, determining it is “not in the best interests of the United States.” 

White House counsel David Warrington wrote Monday in a letter addressed to the National Archives and Records Administration (NARA) and obtained by Fox News Digital that Trump “does not uphold the former President’s assertion of privilege” over records sought in four congressional probes. The letter directs NARA to provide the materials to Congress.

The dispute centers on documents related to investigations into Biden’s health, alleged politically motivated probes into Trump and his allies, and the Biden family’s financial dealings, which Republicans argue go to the heart of Congress’s constitutional authority to conduct oversight.

That means that the White House is telling NARA to turn over anything about the “cover-up” of “Biden’s health and cognitive decline.” Imagine all the potential documents that could involve — we could see all the machinations and who specifically did what regarding any concealing of his cognitive decline. 

“The abuse of the autopen that took place during the Biden Presidency, and the extraordinary efforts to shield President Biden’s diminished faculties from the public, must be subject to a full accounting to ensure nothing similar ever happens again,” Warrington wrote, quoting a prior letter.

Warrington had previously weighed in when Trump denied the executive privilege regarding the autopen issue. 

Keep reading

Study: Lifetime Cannabis Use Not Associated With Cognitive Decline or Dementia Risk in Older Adults

Cannabis use by older adults is not associated with either accelerated cognitive decline or greater risk of dementia, according to findings published in the journal BMJ Mental Health.

Investigators affiliated with Yale University and the University of Oxford in the United Kingdom assessed cognitive performance in lifetime cannabis consumers and non-users across various domains — including memory, intelligence, and problem solving. Data was drawn from two large nationally representative cohorts (the UK Biobank and the US Million Veteran Program), consisting of several hundred thousand participants.

Researchers reported that those with a history of cannabis use “demonstrated significantly better cognitive performance,” a finding that is consistent with prior studies. Cannabis use “was not associated with increased risk of dementia” and researchers found “no supporting evidence of a causal link with [longitudinal] cognitive decline in later life.”

The study’s authors concluded: “This study represents one of the largest observational investigations to date examining the relationship between cannabis use, cognitive function and dementia risk in older adults. … Our findings are broadly consistent with prior population-based longitudinal studies that have not observed accelerated age-related cognitive decline associated with cannabis use. … Clinicians can consider that occasional or prior cannabis use may not be a major contributor to cognitive aging in this population.”

Commenting on the findings, NORML’s Deputy Director Paul Armentano said: “These results contradict one of the more prominent and longstanding stereotypes about cannabis and cannabis consumers. It is unfortunate that these stereotypes often go unchallenged in the media and elsewhere. It is even more unfortunate that studies refuting these long-held stereotypes seldom receive the type of mainstream attention they deserve.”

Several other recent studies have reported similar results. For example, an Israeli study of over 67,000 older adults reported that participants with a history of cannabis use “performed better across all cognitive domains: attention, executive function, processing speed, visual and working memory. … Additionally, past use was associated with a slower decline in executive function.”

A Danish study similarly concluded that cannabis consumers experienced “significantly less cognitive decline” over their lifetimes than did non-users.

Most recently, a study published in January in the Journal of Studies on Alcohol and Drugs concluded: “Greater lifetime [cannabis] use was also associated with better performance on cognitive tasks assessing learning, memory, processing speed, and task switching, aligning with growing evidence of potential neuroprotective effects of cannabis in aging populations. … This study adds to a growing body of evidence that cannabis use may be associated with greater brain volume and cognitive performance in aging adults, especially in regions rich in cannabinoid receptors.”

Keep reading

Biden Autopen Investigation is Ongoing and NOT Closed

Fox News reported on Thursday that the Justice Department’s investigation into Biden’s autopen is ongoing – NOT closed – as previously reported by The New York Times, CBS News, and NBC News.

Fox News cautioned that Joe Biden is not the target of the investigation.

On Wednesday, The New York Times and other outlets, citing sources, reported that prosecutors in Jeanine Pirro’s office dropped the criminal case into whether Joe Biden’s aides unlawfully used the autopen to issue pardons.

According to Fox News, the Biden autopen investigation is ongoing.

Per Fox News: It is also clear that the target of any potential prosecution would NOT be former president Biden himself, “It’s hard to imagine how [Biden] could be criminally liable for pardon power,” said the senior DOJ official, describing that power as basically limitless.

The Oversight Project broke the story about the Biden autopen scandal wide open after they discovered thousands of acts of clemency and executive actions were signed with an autopen rather than a wet signature.

Keep reading

The Biden Autopen Probe Ends the Way So Many Others Do

Tell me if you’ve heard this before.

Former President Joe Biden avoids charges after federal prosecutors closed the probe into his use of an autopen to sign pardons and other documents. Prosecutors in Washington reviewed the case, examined whether Biden authorized the signatures himself, and decided there were no crimes committed.

Like March that comes in like a lion, the investigation launched with big promises but ended quietly, adding to the increasingly rotten pattern in which scandals evaporate without consequences.

Last June, President Donald Trump ordered an investigation into whether the Biden administration used an autopen to sign key presidential documents, such as pardons, months after Mr. Trump had claimed his predecessor’s pardons were illegitimate.

Mr. Trump told Attorney General Pam Bondi and the White House counsel in a memo to probe what he claimed was a “conspiracy” to “abuse the power of Presidential signatures through the use of an autopen to conceal Biden’s cognitive decline.”

The order cited a number of executive actions by Biden, including pardons and judicial appointments, and argued: “There are serious doubts as to the decision-making process and even the degree of Biden’s awareness of these actions being taken in his name.” 

Despite concerns that lawmakers and conservative media had about Biden’s lack-of-mental state in his final months, suggesting staff overstepped their roles … crickets.

What are we left with? Another grand declaration of justice that crumbles into nothing, leaving everyone to wonder if some secret shield protects the powerful or if the whole thing was just hot air from the beginning.

Jeanine Pirro leads as U.S. Attorney for the District of Columbia, and her office reviewed Biden’s pardons and actions. Prosectors couldn’t find any law that bans the use of an autopen if the president approves it. Without proof, the case gets dropped.

Keep reading

A Barely Coherent Joe Biden Tells South Carolina Crowd That HE Closed the Border – NOT Trump 

Joe Biden slammed President Trump on Friday evening during a political event in South Carolina.

“We’re honored to welcome President Joe Biden to Columbia on Friday, February 27, for a reception commemorating his pivotal 2020 South Carolina primary victory and thank him for a lifetime of public service,” The South Carolina Democrat Party said.

Joe Biden was a mess when he deplaned in South Carolina.

He wandered over to a woman in a wheelchair, took her phone and froze up before an aide intervened.

Later Friday evening Joe Biden delivered remarks at an event hosted by the South Carolina Democrat Party at the Columbia Museum of Art.

Biden slammed President Trump and blamed Covid for the border crisis during his speech.

Joe Biden absurdly claimed that HE closed the border – NOT President Trump.

“The day I left office, border crossings in the United States were lower than the day that I entered that office and inherited from Trump. He’s – I won’t say it,” Biden said.

“On the day I left office, I handed Trump the strongest economy in the world! In the world! And that’s not hyperbole. That’s a fact!” Biden said even though near record inflation was crushing Americans in January 2025.

Keep reading

James Comer Slams Pam Bondi DOJ After Viral Chart Shows ZERO Arrests — DOJ Still Sitting on Biden Autopen Pardons Trump Says Are Null and Void

The American people are demanding accountability, but the Department of Justice under Pam Bondi is still dragging its feet.

House Oversight Committee Chairman James Comer is publicly blasting the Department of Justice under Attorney General Pam Bondi after investigative reporter Catherine Herridge highlighted a viral chart circulating on X that exposes a jaw-dropping lack of accountability — zero arrests tied to some of the biggest political scandals of the last decade.

The chart lays out a long list of scandals that dominated headlines for years, from the Russia collusion narrative and Benghazi to election fraud and the Biden autopen scandal, and they all share the same outcome: zero arrests.

Keep reading

Researchers Successfully Reverse Alzheimer’s in Mice: Peer-Reviewed Study

Scientists have reversed Alzheimer’s disease in mice, potentially showing a pathway to treat the illness among humans, according to a Dec. 22 peer-reviewed study published in the Cell Reports Medicine journal.

Alzheimer’s is traditionally considered irreversible. In the study, researchers treated two groups of mice with P7C3-A20, a pharmacologic agent. One group carried human mutations related to amyloid processing, while the other carried a tau protein mutation. Both amyloid and tau pathologies are two major early events of Alzheimer’s.

Researchers say that as mice develop brain pathologies resembling Alzheimer’s, they are ideal subjects to test how P7C3-A20 affects Alzheimer’s in humans.

Among the amyloid mice, treatment with P7C3-A20 was found to have resulted in restoring the proper balance of Nicotinamide adenine dinucleotide (NAD+), which is a cellular energy molecule and a major driver of Alzheimer’s disease. As people age, NAD+ levels decline in their bodies, including the brain. Without proper NAD+ balance, the cells are unable to execute critical processes necessary for proper functioning.

The treatment was found to have reversed blood-brain barrier deterioration, DNA damage, oxidative stress, and neuroinflammation, researchers wrote. The blood-brain barrier maintains nutrient and hormone levels in the brain while protecting the organ from toxins and pathogens.

The treatment enhanced synaptic plasticity and hippocampal neurogenesis, a process in which new functional neurons are generated.

Keep reading

Is There Already a Cure for Alzheimer’s?

Therapies administered to treat Alzheimer’s disease could be doing more harm than good, while modern medicine ignores known effective treatments. This is according to a recent post by “A Midwestern Doctor” on The Forgotten Side of Medicine Substack.

Alzheimer’s is a runaway epidemic in many developed countries, and is increasingly prevalent in Latin America, Africa, and Asia. It is a progressive, neurodegenerative disease that accounts for a majority of dementia cases worldwide, and is one of the top-ranked causes of death in the United States. It involves the buildup of amyloid (protein) plaques in the brain, which causes memory, reasoning, and behavior problems.

Treating the Symptom

Modern therapies focus on removing those plaques, but according to the Substack Reversing Alzheimer’s: The Forgotten Causes and Cures Big Pharma Buried, amyloids build up because of a “mechanism the brain uses to protect itself from stressors that endanger brain tissue.” So attempting to treat Alzheimer’s by eliminating them is “doomed to fail.” In other words, mainstream treatment doesn’t work because it’s treating a symptom, not the source. However, “the money behind this juggernaut has caused research into the real causes of Alzheimer’s to be suppressed.”

The blog cites three peer-reviewed studies revealing new information that deserves attention:

  1. “Reversal of Cognitive Decline: 100 Patients,” published in the Journal of Alzheimer’s Disease & Parkinsonism in 2018;
  2. “Precision Medicine Approach to Alzheimer’s Disease: Successful Pilot Project,” published in 2022 in the Journal of Alzheimer’s Disease; and
  3. The 2024 case series “Sustained Cognitive Improvement in Alzheimer’s Disease Patients Following a Precision Medicine Protocol,” published in the journal Biomedicines.

Bredesen’s Studies & Treatments

A researcher who took part in each of these studies is Dale E. Bredesen, who teaches at UCLA’s medical school in Los Angeles, California. His eponymous protocol involves applying individually targeted therapies to different cases of Alzheimer’s based on their cause.

For Bredesen, plaques are merely a symptom. He identifies six triggers that, over time, play a key role in disease development. They are inflammation, insulin resistance (chronically elevated blood sugar), nutrient and hormonal deficiencies, toxins, blood flow restrictions, and severe or chronic head trauma.

Bredesen’s recommended treatments vary based on these causes, but A Midwestern Doctor mentions a few. “China recently developed a surgery to increase the lymphatic drainage from the brain,” he writes, citing studies that show such drainage necessary “to eliminate amyloid from the brain.” Doctors have also witnessed impressive results with dimethyl sulfoxide (DMSO), a compound that is commonly used topically for pain and inflammation relief.

Doctors in more than 125 countries prescribe it for a plethora of other conditions, but the U.S. Food & Drug Administration limits its use. DMSO.org attributes that reticence to the death of a woman in Ireland in 1965. She had taken DMSO with several other drugs and suffered a severe allergic reaction. Though the causative agent was never determined, popular opinion attributed the death to DMSO, and the FDA shut down clinical trials. Since then, no other deaths attributable to DMSO have occurred.

Keep reading

Microdosing Cannabis Pauses Alzheimer’s Decline in Unprecedented Trial

As the world’s population ages, the number of people living with dementias such as Alzheimer’s disease increases.

Given the lack of curative treatments and the limited effectiveness of available medications, interest in new therapeutic approaches is growing. Among them are cannabinoids from the cannabis plant.

A small new Brazilian study published in the international Journal of Alzheimer’s Disease investigated the effects of microdoses of cannabis extract on patients with mild Alzheimer’s disease. The results found positive effects, without the associated “high” of cannabis.

The logic of microdoses

The study, led by Professor Francisney Nascimento and colleagues at the Federal University of Latin American Integration (UNILA), recruited 24 elderly patients (60-80 years) diagnosed with mild Alzheimer’s.

It evaluated the effects of daily use of an oil prepared from cannabis extract containing THC and CBD in similar proportions and extremely low concentrations (0.3 mg of each cannabinoid). These sub-psychoactive doses do not cause the “high” associated with recreational use of the plant.

The extract used was donated by ABRACE, Brazil’s biggest patient association, and had no contribution from cannabis companies or other funding sources.

“Microdosing” is a term usually associated with recreational use of psychedelics. Given the size of the dose, it would be easy to question whether it could have any effect at all.

Doses below 1 mg of the cannabinoid compounds are not frequently reported in the literature of clinical practice. However, the researchers’ decision to use microdosing did not come out of nowhere.

In 2017, the group led by Andreas Zimmer and Andras Bilkei-Gorzo had already demonstrated that very low doses of THC restored cognition in elderly mice, reversing gene expression patterns and brain synapse density in the hippocampus to levels similar to those of young animals.

Keep reading

Biden Goes Viral for All the Wrong Reasons at Eagles Game

Joe Biden had another embarrassing public appearance Sunday when he showed up to the Philadelphia Eagles-Las Vegas Raiders game at Lincoln Financial Field, bundled against the cold and looking about as lost as you’d expect.

Biden arrived on the sidelines before the 1 p.m. kickoff, standing in the snow with his wife, former First Lady Dr. Jill Biden, as they greeted Eagles owner Jeffrey Lurie. “Go Birds, man, all the way,” Biden said in a clip posted to NBC10’s John Clark’s X account “Gotta win the Super Bowl again.”

From there, it all pretty much went downhill. But, hey, at least he knew he was at a football game…. maybe.

FOX’s NFL account on X posted video of Biden watching the game from the sidelines, and social media quickly erupted in mockery as clips of him staring blankly spread across the platform.

Social media users quickly flooded comment sections with posts targeting Biden’s age and cognitive fitness.

Keep reading